Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC, United States.
Department of Surgery, George Washington University School of Medicine and Health Sciences/Medical Faculty Associates, Washington, DC, United States.
Complement Ther Med. 2020 Dec;55:102552. doi: 10.1016/j.ctim.2020.102552. Epub 2020 Sep 13.
Evidence suggests that cannabinoids may provide therapeutic benefit to patients with dermatologic conditions. The recommendation behaviors of dermatologists with regards to recommending medical cannabis are unknown. We administered a pilot survey to evaluate dermatologists' recommendation behaviors including dermatologic indications and formulation preferences.
A cross-sectional study was done to sample dermatologists using a 24-question survey.
Online survey through SurveyMonkey® that was distributed via Orlando Dermatology Aesthetic and Clinical Conference's mailing list, including thousands of practicing dermatologists.
Descriptive data of dermatologists' recommendation behaviors of medical cannabis are described. Fisher's exact test and Chi-Square tests were used to compare recommendation behaviors by gender, age, years in practice, and residency legality.
The survey was sent to 7176 individuals; of the 28.7 % who opened the email, 2.2 % completed the survey (N = 145). 91 % of dermatologists were in support of medical cannabis use and 13.8 % have recommended it for a dermatologic condition. Atopic dermatitis (45 %) and psoriasis (40 %) were the most common. The most common form of administration was topical (75 %). The main reasons for not recommending medical cannabis were limited knowledge (56 %) and lack of experience (48 %).
Cutaneous inflammatory and pruritic conditions such as psoriasis and atopic dermatitis were the most common reasons dermatologists recommended medical cannabis in our survey. Respondents' recommendation patterns may have been limited by limited by lack of knowledge or experience with medical cannabis. The small sample size of our survey limits generalizability to the dermatology field and warrants further investigation.
有证据表明，大麻素可能为皮肤病患者提供治疗益处。皮肤科医生推荐医用大麻的建议行为尚不清楚。我们进行了一项试点调查，以评估皮肤科医生的推荐行为，包括皮肤病指征和配方偏好。
采用横断面研究，通过 24 个问题的调查对皮肤科医生进行抽样。
通过 SurveyMonkey®进行在线调查，该调查通过奥兰多皮肤病学美容与临床会议的邮件列表进行分发，其中包括数千名执业皮肤科医生。
描述医用大麻推荐行为的皮肤科医生推荐行为描述性数据。Fisher 确切检验和卡方检验用于比较性别、年龄、从业年限和居住地点合法性的推荐行为。
该调查发送给了 7176 人；在打开电子邮件的 28.7%的人中，有 2.2%完成了调查（N=145）。91%的皮肤科医生支持医用大麻的使用，13.8%的人推荐其用于皮肤病。特应性皮炎（45%）和银屑病（40%）最常见。最常见的给药形式是局部用药（75%）。不推荐医用大麻的主要原因是知识有限（56%）和经验不足（48%）。
在我们的调查中，皮肤科医生推荐医用大麻最常见的原因是皮肤炎症和瘙痒性疾病，如银屑病和特应性皮炎。受访者的推荐模式可能受到对医用大麻缺乏了解或经验的限制。我们调查的样本量较小限制了其在皮肤科领域的普遍性，需要进一步研究。
